Meet Our Researchers
My overarching hypothesis is that aberrant DNA looping leads to the development of AML, MDS, and other blood diseases. In healthy DNA looping, cohesin acts like a lasso, bringing together disparate regions of the genome. But if cohesin is mutated—as it is in many blood cancers—that lasso never gets formed or it forms in the wrong place. My team will investigate changes in DNA looping as the disease progresses from one state to the next, with the aim of answering one large question: How, mechanistically, do malfunctions in DNA looping affect gene expression and the development of blood cancers?
I will use my BroadIgnite grant to analyze the chromatin—the complex of DNA, RNA, and proteins that help package our genetic material into chromosomes—in samples from patients at various stages of these blood cancers, who are being treated at the Dana-Farber Cancer Institute. We believe the data that emerges from this study will paint a clearer picture of the role of DNA looping in blood cancers—and shed light on novel mechanisms that we can target therapeutically.